КАРДИООНКОЛОГИЯ: СОВРЕМЕННЫЙ ВЗГЛЯД НА ПРОБЛЕМУ ВЫБОРА ОПТИМАЛЬНОЙ СТРАТЕГИИ ЛЕЧЕНИЯ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА В СОЧЕТАНИИ С ОНКОЛОГИЧЕСКИМ ЗАБОЛЕВАНИЕМ

HighlightsThe article presents an overview of the main studies on the treatment of patients with coronary artery disease and cancer. Abstract Cardiovascular and oncological diseases remain the leading causes of death globally. The combination of coronary artery disease and cancer is becoming more common in clinical practice. Despite the achievements in the treatment of both of these diseases separately, their combination is a considerable issue for specialists. This review article discusses the main issues of managing patients with cancer and coronary artery disease. Moreover, the article presents various treatment strategies, including simultaneous and step-by-step interventions, and shows the current trends of endovascular approach to the treatment of these patients.Основные положенияПредставлен обзор основных исследований по лечению пациентов с ишемической болезнью сердца и онкопатологией. Резюме:Сердечно-сосудистые и онкологические заболевания занимают лидирующие позиции в структуре смертности во всем мире. Сочетание ишемической болезни сердца и онкологического заболевания встречается в клинической практике все чаще. Несмотря на достижения в лечении обеих нозологий по отдельности, их сочетание представляет большую проблему для врачей. В данной обзорной статье обсуждены основные вопросы ведения пациентов с онкологическим заболеванием и ишемической болезнью сердца. В статье описаны разные стратегии лечения, включающие симультанные и этапные вмешательства, показаны современные тенденции эндоваскулярного подхода в лечении данной группы больных

Outcomes of Cryoballoon Ablation in High-and Low-Volume Atrial Fibrillation Ablation Centres: A Russian Pilot Survey

properly cited. Purpose. The results of cryoballoon ablation (CBA) procedure have been mainly derived from studies conducted in experienced atrial fibrillation (AF) ablation centres. Here, we report on CBA efficacy and complications resulting from real practice of this procedure at both high-and low-volume centres. Methods. Among 62 Russian centres performing AF ablation, 15 (24%) used CBA technology for pulmonary vein isolation. The centres were asked to provide a detailed description of all CBA procedures performed and complications, if encountered. Results. Thirteen sites completed interviews on all CBAs in their centres (>95% of CBAs in Russia). Six sites were high-volume AF ablation (>100 AF cases/year) centres, and 7 were low-volume AF ablation. There was no statistical difference in arrhythmia-free rates between high-and low-volume centres (64.6 versus 60.8% at 6 months). Major complications developed in 1.5% of patients and were equally distributed between high-and low-volume centres. Minor procedurerelated events were encountered in 8% of patients and were more prevalent in high-volume centres. Total event and vascular access site event rates were higher in women than in men. Conclusions. CBA has an acceptable efficacy profile in real practice. In less experienced AF ablation centres, the major complication rate is equal to that in high-volume centres

Outcomes of Cryoballoon Ablation in High- and Low-Volume Atrial Fibrillation Ablation Centres: A Russian Pilot Survey

Purpose. The results of cryoballoon ablation (CBA) procedure have been mainly derived from studies conducted in experienced atrial fibrillation (AF) ablation centres. Here, we report on CBA efficacy and complications resulting from real practice of this procedure at both high- and low-volume centres. Methods. Among 62 Russian centres performing AF ablation, 15 (24%) used CBA technology for pulmonary vein isolation. The centres were asked to provide a detailed description of all CBA procedures performed and complications, if encountered. Results. Thirteen sites completed interviews on all CBAs in their centres (>95% of CBAs in Russia). Six sites were high-volume AF ablation (>100 AF cases/year) centres, and 7 were low-volume AF ablation. There was no statistical difference in arrhythmia-free rates between high- and low-volume centres (64.6 versus 60.8% at 6 months). Major complications developed in 1.5% of patients and were equally distributed between high- and low-volume centres. Minor procedure-related events were encountered in 8% of patients and were more prevalent in high-volume centres. Total event and vascular access site event rates were higher in women than in men. Conclusions. CBA has an acceptable efficacy profile in real practice. In less experienced AF ablation centres, the major complication rate is equal to that in high-volume centres